RT Journal Article
SR Electronic
T1 Levels of produced antibodies after vaccination with mRNA vaccine; effect of previous infection with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.05.21254934
DO 10.1101/2021.04.05.21254934
A1 Konstantinidis, Theocharis
A1 Zisaki, Stavroula
A1 Mitroulis, Ioannis
A1 Konstantinidou, Eleni
A1 Kontekaki, Eftychia G.
A1 Romanidoui, Gioulia
A1 Karvelas, Alexandros
A1 Nanousi, Ioanna
A1 Lazidis, Leonidas
A1 Cassimos, Dimitrios
A1 Tsigalou, Christina
A1 Martinis, George
A1 Panopoulou, Maria
YR 2021
UL http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254934.abstract
AB The aim of this study was to estimate the immunogenic effect of mRNA vaccine against SARS-CoV-2. This study included 510 participants who received mRNA vaccine. The measurement of anti-Covid-19 antibodies was performed using the Abbott SARS-CoV-2 IgG quantitative assay (Abbott). Overall, mean title of anti-Spike antibodies was 19319.2±1787.5 AU/ml. Vaccination induced a robust immunogenic response in previous infected with SARS-CoV-2 compared. Additionally, individuals that were asymptomatic after vaccination produced lower levels of antibodies compared to feverish individuals. In conclusion, remarkable high level of anti-Spike Covid-19 antibodies was found after vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the local committee of ethics of University General Hospital of Alexandroupolisand deontology in accordance with the Declaration of Helsinki (Number 1070/11-01-2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.